AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.
What you need to know
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz. Readers should consider how this update fits into wider AI adoption, product strategy, and competitive dynamics.
Key details
- Source: TechCrunch
- Published: 2026-01-13
- Read full article: https://techcrunch.com/2026/01/13/ai-drug-discovery-startup-converge-bio-pulls-in-25m-from-bessemer-and-execs-from-meta-openai-and-wiz/
Why it matters
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz. This development is part of the broader AI trend reshaping the industry.